Crescent Biopharma, Inc.

GlycoMimetics said its pivotal Phase III study of uproleselan in relapsed/refractory AML did not meet its primary endpoint of statistically significant overall survival improvement in the intent-to-treat population. The study enrolled 388 patients across 70 sites in 9 countries, and the follow-up was over 3 years. Median overall survival was 13 months for uproleselan versus 12.3 months for placebo; management called the control-arm survival unprecedented in this setting. Adverse events were consistent with known side-effect profiles of the chemotherapy backbones. Looking ahead, management expects to present a comprehensive data analysis at an upcoming medical meeting, discuss the data with the FDA, share updated plans for uproleselan as soon as reasonably possible, and report back on a revised budget in the coming weeks.

Harout Semerjian framed the quarter as a disappointing but data-rich setback, emphasizing that the company is only a few days into reviewing the results. He stressed that GlycoMimetics remains committed to understanding what the study teaches about uproleselan and the relapsed/refractory AML population, including possible subgroup signals, MRD status, transplant outcomes, and subsequent therapies. His tone was cautious and reflective, with repeated emphasis on working with medical, statistical, clinical, and regulatory experts before making decisions on the program’s next steps.

Brian Hahn did not provide a detailed financial update on the call, but management said the company is “rapidly evaluating ways to reduce our cash burn” as it completes the full analysis of the Phase III data. Harout Semerjian added that GlycoMimetics expects to report a revised budget to investors in the coming weeks. No cash balance, runway, or specific capital-allocation figures were stated in the transcript.

Analysts focused on why the study readout took longer than expected, with management saying patients lived longer than anticipated and that the strong control arm likely drove the delay. Questions also centered on whether the negative Phase III result affects the ongoing NCI trial and the Apollomics study in China; management said the NCI study is in a different line of therapy with a different backbone and endpoint, and declined to comment on Apollomics. Analysts asked about subgroup opportunities, MRD/transplant details, and whether the FDA might support a more limited filing; management said it was too early to speculate, but reiterated that it has had constructive FDA interactions and will review the full dataset before discussing any path forward.